Pharmacyte Biotech, Inc. (PMCB) SEC Filing 8-K Material Event for the period ending Friday, September 20, 2019

Pharmacyte Biotech, Inc.

CIK: 1157075 Ticker: PMCB

View differences made from one to another to evaluate Pharmacyte Biotech, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pharmacyte Biotech, Inc..


Assess how Pharmacyte Biotech, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Pharmacyte Biotech, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Pharmacyte Biotech, Inc. provided additional information to their SEC Filing as exhibits

Ticker: PMCB
CIK: 1157075
Form Type: 8-K Corporate News
Accession Number: 0001683168-19-003157
Submitted to the SEC: Thu Oct 03 2019 4:01:29 PM EST
Accepted by the SEC: Thu Oct 03 2019
Period: Friday, September 20, 2019
Industry: Biological Products No Disgnostic Substances
  1. Bylaw Change
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: